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Rasika S. Mundade 
 
VALIDATION-BASED INSERTIONAL MUTAGENESIS (VBIM) TECHNOLOGY 
IDENTIFIES ADENOMATOUS POLYPOSIS COLI (APC) LIKE PROTEIN (ALP) 
AS A NOVEL NEGATIVE REGULATOR OF NF-κB 
 
Colorectal cancer (CRC) is the third leading cause of cancer related deaths in the 
United States. The nuclear factor κB (NF-κB) is an important family of 
transcription factors whose aberrant activation has been found in many types of 
cancer, including CRC. Therefore, understanding the regulation of NF-κB is of 
ultimate importance for cancer therapy. Using a novel validation-based 
insertional mutagenesis (VBIM) strategy, our lab has identified the novel 
adenomatous polyposis coli (APC) like protein (ALP) gene as a negative 
regulator of NF-κB. Preliminary studies from our lab demonstrated that 
overexpression of ALP led to decreased NF-κB activity by κB reporter assay and 
electrophoresis mobility gel shift assay (EMSA).  The current project aims to 
further evaluate the role of ALP in the regulation of NF-κB signaling in CRC cells. 
We found that overexpression of ALP in human CRC HT29 cells greatly reduced 
both the number and the size of colonies that were formed in a soft agar assay. 
ALP overexpression also decreased the cell growth rate and cell migration ability, 
while shRNA mediated knockdown of ALP showed opposite effects, confirming 
that ALP is a tumor suppressor in CRC HT29 cells. Overexpression of ALP led to 
decreased NF-κB activity by κB reporter assay and condition media assay in 
CRC HT29 cells. Furthermore, immunohistochemical analysis with human colon 
vii 
 
tissues revealed that there is a gradual loss of ALP protein with tumor 
progression. We also found that ALP predominantly localizes in the cytoplasm, 
and binds to the p65 subunit of NF-κB, and might be functioning downstream of 
IκB kinase (IKK). In summary, in this study, we provide evidence regarding the 
tumor suppressor role of ALP in CRC by functioning as novel negative regulator 
of NF-κB. This discovery could lead to the establishment of ALP as a potential 
biomarker and therapeutic target in CRC. 
Tao Lu, Ph.D., Chair 
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CHAPTER I INTRODUCTION 
 
1.1 Colorectal cancer (CRC) and its therapies 
CRC is an epithelial cancer of the colon and rectum, resulting from uncontrolled 
growth of colonocytes, the cells lining the colon and rectum. CRC starts as a 
growth of tissue called a polyp in the colonocytes. These polyps start to grow 
through the layers of colonocytes, and may undergo malignant transformation to 
cancer. This malignant transformation is the result of a progressive accumulation 
of genetic and epigenetic alterations that lead to mutation or deletion of major 
regulator genes, resulting first in hyperplasia moving toward adenoma to 
carcinoma and then metastasis (Mundade R et al. 2014).  
CRC affects men and women of all racial and ethnic groups, and is most often 
found in people 50 years or older. It is the third leading cause of cancer-related 
deaths in the United States. There are approximately 160,000 new cases of CRC 
every year in the United States and approximately one-third of CRC patients die 
from the disease (Jemal A et al. 2009). The lifetime risk of developing CRC is 
about 1 in 20 (5%) and it is expected to cause about 50,830 deaths in 2014. 
(http://www.cancer.org/cancer/colon-cancer-key-statistics). With the established 
and available techniques, there has been considerable advancement in the 
management of CRC; however, mortality still remains high and unchanged with 
the 5-year survival rate of only 62%, which is attributable largely to complications 
of metastatic disease (Hawk ET et al. 2005).  
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There are three types of CRC, including hereditary, familial and sporadic 
diseases. A present estimate is that ~15–30% of CRCs may have a major 
hereditary component. Genetic mutations have been identified as the cause of 
inherited cancer risk in some colon cancer–prone families; these mutations are 
estimated to account for only 5% to 6% of CRC cases overall. About 75% of 
patients with CRC however have sporadic disease with no apparent evidence of 
having inherited the disorder (Mundade R et al. 2014). The development of 
sporadic colon cancer is thought to be influenced by diet, lifestyle, environmental 
factors, and acquired somatic mutations. The spectrum of somatic mutations 
contributing to the pathogenesis of CRC is likely to be far more extensive than 
previously appreciated. Thus identification of other undiscovered genes 
contributing to the development of CRC is essential and may also lead to 
potential prognostic information and targets for novel therapies. 
The pace of recent advances in understanding the molecular basis of CRC and 
expansion in the drugs designed to treat CRC have led to substantial gains in 
quality and quantity of life in CRCs patients. To date, CRC, when discovered 
early, is highly treatable. Even if it spreads into nearby lymph nodes, surgical 
treatment followed by chemotherapy is highly successful. CRC is treated 
depending upon its stage and progression. Stage 0, Stage I and early Stage II 
CRCs are treated with colectomy, Stage III and some Stage II CRCs are treated 
with postoperative adjuvant chemotherapy. Combination chemotherapy with 
multi-drugs including 5-fluorouracil and leucovorin and CapeOx (capecitabine 
and oxaliplatin) and radiation therapy are used to treat recurrent or advanced 
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disease. These treatment regimens now combined with the use of genetically 
engineered monoclonal antibodies in treating CRCs. Although more than a 
million people in the US count themselves as survivors of CRC (Mundade R et al. 
2014), CRC remains a significant public health burden in the US as well as other 
countries around the globe. Like most other cancer therapeutics, these treatment 
regimens are associated with side effects and have not yet shown significant 
efficacy in most instances. In the most difficult cases when the cancer has 
metastasized, treatment can only prolong and add to one’s quality of life. Thus 
identification of new candidate therapeutic target genes involved in the genesis of 
CRC has become an urgent issue in targeted therapy of CRC. 
1.2 NF-κB 
1.21 Signaling pathways activating NF-κB 
The transcription factor NF-κB was discovered as a nuclear factor that binds to 
the enhancer element of the immunoglobulin κ light-chain of activated B cells 
(Sen R et al. 1986). NF-κB plays a central role in the regulation of diverse 
biological processes, including immune responses, development, cell 
proliferation and survival. There are five proteins in the mammalian NF-κB family: 
RelA (p65), RelB, c-Rel, p50/p105 and p52/p100. v-REL (reticuloendotheliosis) is 
an oncoprotein of the REL retrovirus (REV-T). All proteins of NF-κB family share 
a Rel homology domain (RHD) in their N-terminus which is essential for 
dimerization, nuclear translocation as well as binding to cognate DNA elements 
and inhibitor of κB (IκBs).  
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The NF-κB signaling includes the canonical (classical) and the noncanonical NF-
κB signaling pathways. Figure 1, adapted from Horie K et al. 2012, illustrates 
both the NF-κB signaling pathways. In the canonical pathway, the family of 
inhibitors called IκBs masks the nuclear localization signals (NLS) of NF-κB 
proteins and keep them sequestered in a latent, inactive, IκB-bound complex in 
the cytoplasm. When a cell receives any of a multitude of extracellular signals 
like stress, cytokines, free radicals, radiations such as lipopolysaccharides (LPS), 
tumor necrosis factor α (TNFα) or interleukin-1 (IL-1), it activates its receptor 
respectively. Through a variety of adapter proteins and signaling kinases this 
leads to an activation of IκB kinase (IKK), which in turn phosphorylates IκB 
(Leonardo MJ et al. 1987) and leads to its degradation by the proteasome. The 
NF-κB complex rapidly enters the nucleus where it can 'turn on' the expression of 
target genes involved in cell proliferation, cell survival, cell differentiation, and 
immune response.  
In the noncanonical pathway, p100/RelB complexes are present in an inactive 
state in the cytoplasm. Receptor signaling through B-cell activation factor (BAF), 
CD40 ligand (CD40L), receptor activator for nuclear factor κB (RANK) or 
lymphotoxin α1, β2-receptor (LTα1β2R), leads to activation of IKKα by the NF-κB-
inducing kinase (NIK), which in turn activates IKKα complexes. The IKKα 
complexes phosphorylate C-terminal residues in p100, which leads to 
ubiquitination and proteasomal processing of p100 to p52. p52/RelB complexes 
then translocate to the nucleus and induce target gene expression.  
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1.22 The NF-κB signaling pathway and cancer 
The molecular identification of p50 subunit of NF-κB as a member of the REL 
family provided the first evidence that linked NF-κB to cancer (Thanos D et al. 
1995). Constitutive NF-κB activation has been noted in 95% of all cancers 
(Aggarwal B et al. 2006). Oncogenic role of NF-κB involves regulation of cell 
proliferation, control of apoptosis, promotion of angiogenesis, and stimulation of 
invasion/metastasis in cancer cells. Since NF-κB plays a very important role in 
immune cell function, it is frequently associated with the development of 
leukemia and lymphoma, cancers of the bone marrow and lymph nodes 
respectively. NF-κB can be constitutively activated in blood cells in response to 
growth factors and cytokines. Expression of certain viral oncoproteins or by 
chromosomal rearrangements that affect genes that encode NF-κB or IκB 
proteins lead to lymphomagenesis (Baud V et al. 2009).  
Though the role of NF-κB in lymphomagenesis was somewhat anticipated, 
numerous studies have now documented the role of NF-κB in the development of 
solid malignancies. NF-κB has been shown to be involved in the development of 
carcinomas — cancers of epithelial origin, such as breast cancer. Constitutive 
NF-κB DNA-binding activity is seen in mammary carcinoma cell lines and primary 
breast cancer cells of human and rodent origin (Cogswell PC et al. 2000). NF-κB 
is also shown to have a complex role in another inflammation-linked cancer, 
hepatocellular carcinoma (HCC), the most common form of liver cancer. A study 
by Pikarsky E et al. 2004, demonstrated that inhibition of NF-κB activation in  
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Figure 1. Canonical and noncanonical NF-κB activating 
pathways (Adapted from Horie K et al. 2012)  
Abbreviations: BAF, B-cell activation factor; CD40L, CD40 ligand; 
DNA, deoxyribonucleic acid; IKK, IκB kinase; IL-1, interleukin-1; 
LPS, lipopolysaccharide; LT-α
1
β
2
, lymphotoxin α
1
, β
2
-receptor; NIK, 
NF-κB inducing kinase; NLS, nuclear localization signal; R, 
receptor; TNFα, tumor necrosis factor α.  
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hepatocytes of mice with homozygous knockout of p-glycoprotein gene Mdr2−/− 
retarded and reduced HCC development via apoptosis. 
Furthermore, it has been demonstrated that upregulation of the NF-κB levels is 
involved in both the progression and increase of metastatic potential of 
melanoma, the most aggressive form of skin carcinogenesis (Kashani-Sabet M et 
al. 2004). Additionally, the NF-κB transcriptional factors are also shown to be 
constitutively activated in the majority of pancreatic cancers and are involved in 
the regulation of numerous aspects of pancreatic tumor development and 
progression. 
1.23 The role of NF-κB signaling pathway in CRC 
With the given role of NF-κB in different cancer types, the signature changes in 
NF-κB and its involvement in CRC is not surprising. NF-κB coordinates immune 
host defense by regulating inflammatory response and providing a barrier against 
extrinsic hazard. Deregulation of this homeostasis predisposes to inflammatory 
bowel disease (IBD) and CRC. NF-κB has been recognized as a key player in 
the initiation and propagation of CRC. Human colon tumor samples and sporadic 
adenomatous polyps are found to have increased NF-κB activity (Hardwick JC et 
al. 2001; Lind DS et al. 2001). The first concrete evidence that linked NF-κB to 
CRC came from a study that demonstrated that down regulation of RelA 
expression in IL-10 deficient mice with constitutively active NF-κB significantly 
reduced IBD symptoms and hence the risk of CRC (Kuhn R et al. 1993). Studies 
with Azoxymethane (AOM)/Dextran Sodium Sulfate (DSS) mouse models of 
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colitis-associated colon cancer (CAC) and animal model carrying a conditional 
disruption of IKKβ have been used to show that IKKβ-driven NF-κB activation 
within intestinal epithelial cells (IECs) is essential for development of colonic 
adenomas (Okayasu I et al. 1996). Sakamoto K et al. 2009, showed that 
constitutive NF-κB activation in CRC plays a key role in promoting angiogenesis 
and tumor growth. Recently it has been demonstrated that, mutant p53 prolongs 
NF-κB activation and promotes chronic inflammation and CAC (Cooks T et al. 
2013). Studies like these are only a few of several lines of evidence suggesting 
that NF-κB plays a crucial role in CRC development.  
Consistent with this role of NF-κB, it is also observed that several NF-κB 
inhibitors are useful alone or in combination with cancer therapies to cause tumor 
cell death or growth inhibition. Advanced CRC uses chemotherapy, however 
most cases develop tolerance to such treatments and thus new strategies are 
required to replace or complement current therapies. It has been observed that 
some tumor cells secrete factors cause constitutive NF-κB activation and lead to 
resistance to chemotherapy. An interesting study by Shakibaei M et al. 2013, 
demonstrated that combination treatment regimen of 5-fluorouracil (5-FU) and 
curcumin in CRC cells enhances the effect of chemotherapy against CRC cells 
by inhibition of NF-κB. The relationship between CRC development and NF-κB is 
becoming extremely clear, making NF-κB the subject of much active research 
and represents possible novel drug targets for pharmaceutical treatments of anti-
cancer therapy. 
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1.3 Adenomatous polyposis coli (APC) and APC like protein (ALP) 
1.31 APC gene and its role in CRC 
Adenomatous polyposis coli (APC) also known as deleted in polyposis 2.5 
(DP2.5) is a protein that is encoded by the APC gene in humans. The human 
APC gene is located on the long (q) arm of chromosome 5 in band q22.2. APC is 
classified as a tumor suppressor gene and was identified through its association 
with an inherited syndrome of CRC known as familial adenomatous polyposis coli 
(FAP). APC mutation is one of the earliest mutation in CRC progression and 
mutation or loss of APC is found in more than 80% of all the colorectal adenomas 
and carcinomas (Goss KH et al. 2000). In order for cancer to develop, both 
copies of the APC gene must be mutated, resulting in full length loss of protein in 
tumor cells.  This mutational inactivation of APC is seen in both familial and 
sporadic tumors, and must be followed by other mutations to become cancerous. 
In carriers of APC inactivating mutations, the risk of CRC by age 40 is almost 
100% (Markowitz SD et al. 2009).  
APC plays a critical role in governing physiological processes like cell 
proliferation, differentiation, metastasis and apoptosis. Dysregulation in the levels 
of APC alters these important processes and predisposes a person towards 
inherited and sporadic CRC. APC is a key player in the Wnt/β-catenin pathway 
and regulates the cytoplasmic concentrations of β-catenin by regulating its 
degradation. β-catenin is an essential component of the adhesion junction 
complex and also has a role in modulating gene expression. Figure 2, adapted 
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from Eisenmann DM, 2005, illustrates the canonical Wnt/β-catenin signaling 
pathway. The APC protein builds a complex with glycogen synthase kinase 3-
beta (GSK-3β) and axin which then further binds β-catenin in the cytoplasm. In 
the absence of signal, β-catenin can be sequentially phosphorylated by casein 
kinase 1 (CK1) and GSK-3β, which is a target for ubiquitination and degradation 
by the proteasome. Due to the key role APC plays in leading β- catenin to 
degradation, in the absence of functional APC, free β-catenin will be 
accumulated in the cytoplasm and associated with members of T-cell factor 
(TCF) family of transcription factors, which then translocate to the nucleus, bind 
to the TCF consensus binding sites and trigger the transcription of specific target 
genes. The transcriptional targets of this pathway govern cell growth, migration, 
differentiation and apoptotic processes (Clevers H, 2006). 
The altered functional role of APC in CRCs thus leads to dysregulation of the β-
catenin/TCF pathway, affecting the transcriptional profile in these cells, leading to 
cell overgrowth, altered cell migration and chromosome instability.  
1.32 Cross-talk between APC and NF-κB signaling pathway 
Interestingly, crosstalk between APC and NF-κB pathway has been proposed. An 
interesting study by Shaked H et al. 2012, showed that in constitutive IKKβ 
(EE)(IEC) transgenic mouse intestinal epithelial cells (IECs), chronic epithelial NF- 
κB activation accelerates APC loss and intestinal tumor initiation through iNOS 
up-regulation. The results from this study suggested that, persistent NF-κB 
activation in IEC may increase β-catenin expression and tumor progression by 
11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. A canonical Wnt/β-catenin signaling pathway (Adapted from 
Eisenmann DM, 2005; Wormbook.org)  
Abbreviations: APC, adenomatous polyposis coli; CBP, CREB binding 
protein;  CK1α, casein kinase 1α; Dsh, phosphoproteinDishevelled; GSK-
3β, glycogen synthase kinase 3β; LRP, lipoprotein receptor-related protein; 
TCF, T-cell factor.  
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accelerating APC loss. This study suggested that functional cross-regulation 
between APC and NF-κB signaling pathway has complex roles in the 
pathogenesis of certain diseases including CRC.  
1.33 Similarity between ALP and APC  
Using VBIM technology, we identified the novel adenomatous polyposis coli 
(APC) like protein (ALP) gene as a novel negative regulator of NF-κB in an 
unbiased fashion (discussed later in introduction and results section). Due to the 
great similarity of this novel regulator with APC and the important role APC plays 
in colon cancer, we name this novel regulator as APC Like Protein. ALP also has 
official alternative name as Armadillo Repeat-Containing Protein 4, (ARMC4) or 
Ciliary Dyskinesia, Primary 23 (CILD23). To date, very few studies have been 
devoted to this novel and interesting protein. ALP belongs to Armadillo repeat 
(~40 amino acids long) containing protein superfamily. Other members in this 
protein superfamily include APC, β-catenin and α-importin. ALP is located on 
chromosome 10p12.1-p11.23, contains 20 exons encoding a protein of 1,044 
amino acids. ALP has 10 ARMs and one HEAT repeat. In contrast, APC is 
located on chromosome 5q21-q22 and encodes a protein of 2,843 amino acids. It 
has 6 Armadillo repeat motifs (ARMs) and 4 HEAT repeats. Although a role for 
ALP in cancer has not been reported, ARM proteins are known to be involved in 
a variety of processes including cell migration and proliferation, signal 
transduction, and maintenance of overall cell structure. It is also reported that 
tandem ARM-repeat units fold together as a super helix, forming a versatile 
platform for interactions with many protein partners (Tewari R et al. 2010). Based 
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on the functional significance of proteins in this superfamily and their important 
role in CRC regulation, it is very likely that ALP will also play an important role in 
regulation and development of CRC.  
1.4 Validation based insertional mutagenesis (VBIM) technology 
1.41 Design and novelty of VBIM technology 
Given the crucial role of NF-κB in the proliferation and progression of CRC 
(Prasad S et al. 2010), manipulating NF-κB activity could be critical in the 
treatment of CRC. Towards this end, we used a novel VBIM strategy to identify a 
novel regulator of NF-κB, and further evaluate its role in regulating the NF-κB 
signaling in CRC cells at the molecular and biological level. 
VBIM technology is a novel technique developed in our laboratory to isolate 
dominant mutant clones overexpressing the protein of interest. This innovative 
strategy distinguishes itself from other traditional approaches by several 
advantages. Owing to its technical simplicity, ability to infect both the dividing and 
non-diving cells, and robust target validation, VBIM has broad range of 
applications. The characteristic feature of this technique is random integration of 
a strong cytomegalovirus (CMV) promoter into the genomes of mammalian cells 
in tissue culture. Figure 3, adapted from Lu T et al. 2009, illustrate the schematic 
diagram of the VBIM lentiviral vectors. The VBIM vector has lentivirus backbone 
and splice donor sequence. A tet-operator (TO) element upstream of CMV 
promoter regulates its activity, following introduction of the TR-KRAB fusion 
protein which binds to this element in a doxycycline-dependent manner to 
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suppress the function of the adjacent promoter. It also has internal green 
fluorescent protein (GFP) reporter gene and internal ribosome entry site (IRES) 
downstream of GFP. The cellular protein encoded downstream of the insertion 
site is translated by the IRES and has a FLAG tag. The vector contains splice 
donor site (SD), and separate constructs for three different reading frames of 
FLAG-SD.  
The working principle of VBIM lentiviral vectors is demonstrated in Figure 4, 
adapted from Lu T et al. 2009. Libraries of cells are generated using VBIM, with 
one or two different integrations of a strong CMV promoter randomly into the 
genomes of mammalian cells. VBIM vectors have LoxP sites on both ends of the 
vector. The promoter stimulates high expression of downstream genes 
generating dominant mutants. The mutant phenotype is attributed by the 
overexpressed protein (Figure 4A and B). The overwhelming advantage of this 
technique is the ease with which overexpressed proteins are identified. Any 
protein, as long as it confers a selectable phenotype can be identified with this 
technique. 
Validation is done by using Cre. Cre is a recombinase that silences or removes 
the highly active CMV promoter. Reversion of mutant phenotype back to the wild 
type upon removal of CMV promoter provides conclusive genetic evidence that 
the insertion caused the mutation (Figure 4C). Upon excision of the vector by 
Cre, the gene might be left with very small footprint from the VBIM vector 
however, this does not affect the gene property and the cell can be reversed from 
mutant phenotype to wild type phenotype. The location of site of insertion is 
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identified by cloning and aligning it to human genome database. After gene 
identification, full length cDNA of the gene is expressed in normal cells and the 
overexpression of protein in these cells confirms whether the insertion event is 
the cause of the change of the cell phenotype. 
1.42 Using VBIM to identify ALP as the negative regulator of NF-κB 
signaling  
The long term goal of our lab is to understand the regulation of NF-κB pathway. 
Elucidating the underlying molecular mechanisms in the regulation of this 
pathway would lead to potential prognostic information and novel therapies 
targeted at inhibiting this hyper activated pathway. Previously, using VBIM 
technology, our lab has successfully identified and confirmed ALP gene as a 
novel negative regulator of NF-κB in an unbiased fashion (unpublished work). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Schematic diagram of the VBIM lentiviral vectors (Adapted 
from Lu T et al. 2009)  
Abbreviations: CMV, cytomegalovirus promoter; cPPT, central polypurine 
tract; GFP, green fluorescent protein; IRES, internal ribosome entry 
sequence; Lox P, site for Cre-mediated recombination; LTR, long terminal 
repeat; SA, splice acceptor site; SD, splice donor site; SIN, self-inactivating 
LTR; TO, tetracycline operon; WPRE, woodchuck hepatitis virus post-
transcriptional regulatory element. 
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Figure 4. Working principle of the VBIM lentiviral vectors (Adapted 
from Lu T et al. 2009).  
(A)A random gene in the genome of mammalian cells is represented (right). 
This gene attributes wild type cell phenotype. The CMV promoter is flanked 
on both sides with LoxP sites (left). (B)Following virus infection, the VBIM 
vectors randomly integrate into the gene and depending on the site of 
integration of CMV promoter will drive expression of different genes. This will 
attribute to changing cell from wild type to mutant phenotype. (C)To validate 
if the change in wild type to mutant phenotype is attributed by the VBIM 
insertion event, Cre recombinase is used to excise the vector from LoxP 
sites on both ends. If the cell phenotype changes back from the mutant to 
wild type, it proves that the insertional event was the cause of change of the 
cell phenotype. 
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To screen for negative regulators of NF-κB, Dr. Lu et al. used Z3 cells. Z3 cells 
have constitutively active NF-κB. These cells were obtained following chemical 
mutagenesis and selection for zeocin resistance of parental 293-thymidine 
kinase (TK)/zeocin resistance (Zeo) cells. The Z3TK/Zeo dual lethal selection 
system would allow cells with constitutive NF-κB to express the Zeo and TK 
genes. Active TK would then convert ganciclovir (GCV) into toxic product to kill 
Z3 cells, whereas expression of Zeo gene would allow cells to be resistant to Zeo 
treatment.  Therefore, Z3 cells die in GCV and survive in Zeo (Lu T et al. 2004).  
The expression of a negative regulator of NF-κB in Z3 cells would cause the 
constitutive NF-κB activity to shut down, a phenotype can be selected for by 
requiring the cells to survive in GCV and die in Zeo (Lu T et al. 2004). By using 
this novel selection system, Dr. Lu identified ALP as a negative regulator of NF-
κB (Lu T et al. unpublished data). 
1.5 Central hypothesis and specific aims 
Given the role of NF-κB signaling in CRC, the central hypothesis of this proposal 
is that, the ALP gene negatively regulates NF-κB signaling and functions as a 
tumor suppressor in CRC. My work follows to further evaluate the role of ALP in 
regulating the NF-κB signaling in CRC cells at the molecular and biological level 
by pursuing the following two specific aims: 
Aim 1: Study the role of ALP in regulating NF-κB signaling at molecular 
level in colon cancer cells. 
Rationale: Using VBIM technique, Dr. Lu has identified ALP gene as a negative 
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NF-κB regulator. It has long been appreciated that regulation of NF-κB signaling 
pathway is complex and given its role in the initiation and progression of CRC, 
understanding the regulation of NF-κB pathway at molecular level is of ultimate 
importance. Although we identified ALP as a negative regulator of NF-κB, 
however, the exact molecular mechanism of the regulation of complex NF-κB 
signaling by ALP is completely unknown. In order to provide new targets for 
preventive and therapeutic interventions in CRC, understanding the molecular 
mechanism by which ALP regulates NF-κB signaling and explore if similar results 
are observed in human colon cancer cells is extremely important. 
Aim 2: Determine the biological effects of ALP in colon cancer cells. 
Rationale: NF-κB signaling pathway is aberrantly activated in colon cancer and in 
Aim 1 we found that hyper activity of NF-κB can be inhibited by ALP. NF-κB 
transcription factors are critical in regulating genes with whole variety of functions 
like cell proliferation, differentiation, inflammation, and it is apparent that NF-κB 
has a key role in genesis of colon tumors. Using Mass Spectrometry protein 
identification method, Dr. Lu et al. identified that ALP was pulled down together 
with p65 (data not shown). We postulate that by associating with NF-κB, ALP will 
down regulate the transcription of these genes and will ‘turn off’ the function of 
these genes. The next logical step following this is to test the effect of ALP on the 
biological attributes of CRC cells like proliferation, colony size, metastasis and 
invasion ability with biochemical and genetic approaches. 
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CHAPTER II MATERIALS AND METHODS 
 
2.1 Cell lines and antibodies:  
The human embryonic kidney (HEK) 293 cells, also referred as 293 cells, and 
293-NF-κB reporter cells (Lu T et al, 2004) were cultured in Dulbecco’s modified 
Eagle’s media supplemented with 100 U/ml penicillin, 100 mg/ml streptomycin, 
and 10% fetal bovine serum (FBS). The HT29 and DLD1 colon cancer cell line 
were purchased from the American Tissue Culture Collection (ATCC) 
(Manassas, VA, USA) and were cultivated in RPMI1640 media with 100 U/ml 
penicillin, 100 μg/ml streptomycin, and 10% fetal calf serum. Experiments were 
carried out when the cells reached 90% confluence. The following antibodies 
were obtained from commercial sources: anti-ALP, anti–NF-κB p65, and anti-
IκBα were from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). Anti-β-actin 
and anti-Flag were from Sigma-Aldrich (St. Louis, MO, USA). 
2.2 Construction of stable ALP overexpressing or shALP HT29 cells:  
ALP protein was cloned into the lentiviral vector as a full length cDNA or shRNA 
pool (containing 5 different shRNA constructs) against ALP were purchased from 
Sigma-Aldrich (St. Louis, MO, USA). Viruses were generated and used to infect 
HT29 cells. Since both the lentiviral vector and the shRNA pool carry the 
puromycin resistance marker, puromycin-resistant clones were selected in 
1μg/ml puromycin after virus infection. Approximately 10 days after puromycin 
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selection, cells were pooled and tested for the best overexpression and 
knockdown by the Western Blot method with antibodies against ALP. 
2.3 Transfections and luciferase assays:  
For NF-κB luciferase assays, the κB-luciferase construct p5XIP10 κB (contains 
five tandem copies of the NF-κB site from the IP10gene) (Lu T et al. 2004) was 
transfected transiently into the cells and luciferase activity was assayed 48 h 
later. A β-galactosidase (β-gal) construct was co-transfected to normalize for 
transfection efficiency. The cells were then washed with cold phosphate-buffered 
saline (PBS), and lysed in 80μl of 5X lysis buffer from Promega Corporation 
(Madison, WI, USA). After incubation on ice for 15–20min, cell debris was 
pelleted at 15,000 g, for 5 min at 4°C. A measure of either 30 μl of luciferase 
assay substrate or β-gal substrate (Promega Corporation) was added to 20 μl of 
supernatant solution before being read in a luminometer. The relative 
luminescence was normalized to the optical reading of β-gal (Bio-Rad 
Laboratories, Hercules, CA, USA). 
2.4 Western analysis: 
Cells were cultured to 95% confluency, treated or untreated with IL-1β for 
different times, as indicated in the descriptions of individual experiments and 
washed with 1X PBS and pelleted at 5,000 g at 4°C for 4 min. Cell pellets were 
lysed with RIPA buffer [1X PBS/1% Nonidet P-40/0.5% sodium 
deoxycholate/0.1% sodium dodecyl sulfate (SDS)]. Cellular debris was removed 
by centrifugation at 15,000 g for 10 min. The amount of protein in the supernatant 
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solution was determined, and samples were heat-treated in 2X SDS sample 
loading buffer at 100°C for 5 min. Equal amounts of samples were fractioned by 
SDS/PAGE and transferred to nitrocellulose membranes. Membranes were 
blocked in 5% non-fat skim milk powder in PBS for an hour and then probed with 
primary antibodies, which were visualized with horseradish peroxidase-coupled 
secondary antibodies by using the Enhanced Chemiluminescence (ECL) 
Western Blotting Detection System (PerkinElmer Life and Analytical Sciences, 
Waltham, MA, USA).Human IL-1β (National Cancer Institute Biological 
Resources Branch Preclinical Repository) was used at 10ng/mL. 
2.5 Reverse PCR, quantitative real-time PCR and genomic PCR analysis: 
The total RNA was extracted with the TRIzol reagent at room temperature 
following the protocol provided by Invitrogen Life Technologies (Carlsbad, CA, 
USA). Random primers were designed using the Primer Express 3.0 software, 
and cDNA was made by reverse PCR from total RNA of 293 cells by using the 
SuperScript III First-Strand Synthesis System (Invitrogen). Real-time PCR was 
performed for each cDNA with Econo Taq PLUS Green 2X PCR Master Mix 
(Lucigen, Middleton, WI, USA), with gene-specific primer pairs. Samples were 
amplified according to standard PCR procedure. For Quantitative PCR (qPCR) 
experiments, cells were cultured to 80–90% confluency and were untreated or 
treated with IL-1β for 60 min. Samples were analyzed by using FastStart 
Universal SYBR Green Master (ROX) (Roche Diagnostics) qPCR reactions. The 
quantitative mRNA expression was calculated based on the 2-ΔΔCT method 
(Kreuzer KA et al. 1999). GAPDH was selected as the housekeeping gene for 
22 
 
normalization; each gene was running along with GAPDH and difference 
between threshold cycles (CT) was designated as ΔCT. ΔΔCT is the difference 
between their respective controls.  
The genomic DNA was extracted using the QIAamp DNA mini kit from Qiagen 
(Valencia, CA, and USA). The genomic PCR was performed with 100 ng of 
genomic DNA and samples were amplified according to standard PCR 
procedure. All reactions were independently repeated at least three times to 
ensure the reproducibility of the results. GAPDH was used as a control for all 
target genes. Primer Express 3.0 software was used to design primers after 
obtaining the primer sequences from National Center for Biotechnology 
Information (NCBI). 
2.6 Co-immunoprecipitation assay: 
Cells cultured in 15-cm plates to 95% confluency were lysed in co-
immunoprecipitation buffer (1%Triton X-100, 50 mMTris-HCl, pH 7.4, 150 
mMNaCl, 1 mMEDTA, 1 mM sodium orthovanadate, 20 μM aprotinin, and 1 
mMphenylmethanesulfonyl fluoride and pepstatin A). Prewashed immobilized 
protein A/G (Pierce) was premixed with anti-p65 for 1 h, and then mixed with cell 
lysates with equivalent amount of proteins at 4°C overnight. Gel beads were 
washed four times with 20 volumes of IP buffer with rotation at 4°C for 5 min 
each time. At the last step, the gel beads were resuspended in an equal volume 
of 1XSDS sample loading buffer (6% glycerol, 1% β-mercaptoethanol, 2% SDS, 
50 mMTris-HCl, pH 6.7, 0.004% bromophenol blue) and boiled for 5 min. 
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Supernatant was then separated by SDS/PAGE. For anti-Flag-M2 antibody, 
EZView beads were used (Sigma-Aldrich). 
2.7 Conditioned media assay: 
The 293 cells were seeded into 12-well plates, cultivated to 90% confluency, and 
transfected with different plasmids: empty vector, WTALP, shALP. After 24 h of 
transfection, the media were replaced and the cells were kept for an additional 48 
h. The conditioned media were collected, floating cells were pelleted at 3,000 g 
at 4°C, for 10min, and the supernatant was aliquoted into sterile tubes and either 
used immediately or stored at -80°C. The media were then used to treat 293-NF-
κB reporter cells and luciferase assay was performed as previously described. 
2.8 Cell growth and soft agar assays: 
HT29 control cells or cells with overexpression or shALP knock down of ALP 
were plated in triplicates at 20,000/well in a 6-well plate with 3 ml of medium and 
the medium was changed every 3 days. Cell number was counted on different 
days using a cell counting chamber.  
For soft agar assays, type VII agarose (Sigma Aldrich) was autoclaved and 
mixed with RPMI1640 cell growth medium. Cell culture dishes were coated with 
1.2% agarose as the bottom layer. Cells were resuspended in 0.6% of soft 
agarose, and plated on top of the bottom layers. Cells were cultured in the 
semisolid medium for about 2–3 weeks. The colonies formed were checked 
under a microscope and measured and counted with the help of ImageJ software 
(ver. 1.47t). 
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2.9 Migration assay: 
The Boyden chamber containing cell culture inserts with polycarbonate 
membrane at the bottom with a pore size of with 8 μM pore size and 6.5-mm 
diameter (Corning-Costar, Lowell, MA, USA) were used. The inserts were coated 
with 0.1% gelatin for 2-3 h at 37°C. HT29 control cells, or cells with the 
overexpression or shRNA knock down of ALP were suspended in serum-free 
RPMI1640 medium and plated in triplicates at 200,000/insert in the upper 
chambers. The lower chambers were filled with 10% FBS RPMI1640 medium. 
The cells were incubated at 37°Cfor 72 h. The inserts were then removed and 
migratory cells at the bottom of the chamber were fixed and stained in a 4% 
paraformaldehyde (PFA)/0.1% Crystal Violet solution, followed by washing in 
deionized water to remove redundant staining. Non-migrated cells remaining at 
the upper side of the membranes were carefully removed with cotton swabs and 
inserts were dried in darkness overnight. The following day stained membranes 
were pictured in five random non-overlapping fields and counted manually at 20X 
objective and 20X eyepiece on a transmitted-light microscope. 
2.10 Immunofluorescence assay: 
293 cells were cultured overnight at 100,000 cells/coverslip coated with 0.1% 
gelatin. Following treatment with IL-1β for 30 min, the cells were fixed with 4% 
PFA for 30 min and were permeabilized for 10 min in blocking buffer (1X 
PBS/0.2% Triton™ X-100/1% bovine serum albumin [BSA]). The two primary 
antibodies, anti-ALP antibody (diluted 1:150) and anti-p65 antibody (diluted 
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1:200) were added and allowed to bind for a minimum of 1 h in blocking buffer 
and the cells were washed three times in PBS for 10 min each to remove excess 
primary antibody. The two primary antibodies were visualized with an anti-rabbit 
IgG secondary antibody with a red fluorescent tag (Alexa Fluor 594 - Molecular 
Probes) and an anti-mouse IgG secondary antibody with a green fluorescent tag 
(Alexa Fluor 488 - Molecular Probes) (diluted 1:2000) respectively. Cells were 
washed three times in PBS for 10 min each and stained with DAPI (Molecular 
Probes) according to the manufacturer’s instructions (Vector Laboratories, 
Burlingame, CA, USA). The coverslips were then inverted onto a glass 
microscope slide, mounted, sealed and viewed using a Zeiss Axiovert 40 CFL 
microscope (60X magnification) and digital photographs were taken. 
2.11 Immunohistochemical analysis of tissue microarray (TMA): 
The colon cancer TMA CO951 (30 cases/95 cores) was purchased from US 
Biomax, Inc. (Rockville, MD, USA). The cores are duplicated; 30 cancer and 8 of 
which has matched normal adjacent tissue and 10 cases of matched metastasis, 
with follow-up data 2 cores per case. All histochemical stains were carried out at 
the IUSM Immunohistochemistry (IHC) Core, by an expert pathologist Dr. 
Constance Temm and included standard deparaffinization in xylene, quenching 
in 1% hydrogen peroxide/methanol for 10 min, and rehydrated through 
sequentially graded ethanols. Antigen retrieval was performed by 
Ethylenediamine-tetraacetic acid (EDTA). Using a DAKO automated 
immunostrainers (DAKO, Carpinteria, CA, USA), the slides were blocked for 30 
min in horse serum and incubated with ALP antibody, followed by incubation with 
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secondary antibody. The Universal ABC Elite kit (Vectastain, Burlingame, CA, 
USA) with 3,3′-diaminobenzidine development was used to visualize antibody 
binding, and the slides were subsequently counterstained with hematoxylin. The 
tissue arrays were stored at 4C and heated to 60C for 1hour before use. 
2.12 Evaluation of immunohistochemical staining: 
The TMA sets were scanned using Images were scanned with the Aperio 
Scanscope Imaging System (Leica Biosystems, Buffalo Grove, IL, USA). The 
TMA tissue cores were individually copied, labeled and stored in a separate 
folder as tiff files. The immunohistochemical staining results of individual core 
tissues were evaluated by an expert pathologist (Dr. George Sandusky), who 
was blinded to patient’s clinocopathological details. The immunohistochemical 
staining was categorized according to a scoring method based on the staining 
intensity (score 0, no staining intensity; score 1, weak staining intensity; score 2, 
intermediate staining intensity; and score 3, strong staining intensity). In the case 
of heterogenous staining within the samples, the respective higher score was 
chosen if >50% of the cells showed higher staining intensity. 
2.13 Statistical analysis 
The data represent the means ± SD from at least three separate experiments 
performed in triplicate. The differences between groups were analyzed using 
Student’s ttest, and a P-value <0.05 was considered statistically significant. 
Statistical analyses were carried out using JMP software (ver. 7.0) 
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CHAPTER III RESULTS 
 
Previously, Dr. Lu et al. identified and confirmed ALP as a negative regulator of 
NF-κB in 293 cells (discussed earlier in introduction section). To follow up this 
preliminary finding, I performed the following experiments: 
3.1 Overexpression of ALP down-regulates the expression of most NF-κB 
inducible target genes 
Dr. Lu et al. have found that in 293 cells, ~46.2% of NF-κB genes were down-
regulated by twofold or more by the overexpression of ALP (microarray data not 
shown). These data demonstrated that the ALP down-regulates the expression of 
most of the NF-κB inducible target genes. Among these genes are chemokines, 
cytokines, growth factors etc., most of which are known to have an important role 
in cancer development (data not shown). Following up on Dr. Lu T et al’s work, to 
confirm the microarray data, I first performed a qPCR to confirm the expression 
of several candidate genes. As shown in Figure 5, the mRNA levels of 
suppressor of cytokine signaling 6 (SOCS6), bone morphogenetic proteins 
(BMP1), Tripartite motif-containing protein 16 (TRIM16), andS100 calcium 
binding protein A3 (S100A3) were strongly induced in IL-1β–treated 293 cells, 
but the induction was substantially less in 293 cells with ALP overexpression. 
These results are consistent with the idea that ALP down-regulates NF-κB 
inducible target gene expression. 
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3.2 Overexpression of ALP decreases NF-κB activity in human colon 
cancer HT29 cells 
Since Dr. Lu et al. have proved that ALP is a negative regulator of NF-κB in 293 
cells; we asked whether ALP could negatively regulate NF-κB in colon cancer 
cells, which usually have high constitutive NF-κB activity. To test the functional 
significance of ALP, we either overexpressed or used shRNA pool to knockdown 
ALP in human colon cancer HT29 cells, which has constitutively active NF-κB (Lu 
T et al. 2004). As shown in Figure 6A, western analysis indicated stable HT29 
lines with expected level of ALP were successfully generated. HT29 with vector 
infection were used as normal control.  Furthermore, a luciferase reporter assay 
in these cells demonstrated that, overexpressing ALP reduced the constitutive 
activity of NF-κB by approximately ten folds, while knocking ALP down enhanced 
this activity (Figure 6B). Therefore, collectively, these data suggest that ALP is a 
strong NF-κB inhibitor in human colon cancer HT29 cells. 
3.3 ALP affects the cell growth, anchorage independent growth, and 
migration in colon cancer HT29 cells 
NF-κB can affect all six hallmarks of cancer through the transcriptional activation 
of genes associated with cell proliferation, angiogenesis, metastasis, tumor 
promotion, inflammation and suppression of apoptosis (Baud V et al. 2009). 
Since our results demonstrated that ALP inhibits the NF-κB pathway in colon 
cancer HT29 cells, we examined the effect of ALP on the biological attributes like 
cell proliferation, tumor size, and metastasis ability in these cells.  
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Figure 5. Regulation of NF-κB–dependent gene expression by ALP 
Confirmation of Illumina array data by qPCR analysis from 293 cells 
overexpressing ALP protein. 293 cells were used as the control. The 
expression of SOCS6, BMP1, TRIM16 and S100A3 was tested, confirming that 
these genes were strongly induced upon IL-1β treatment but significantly 
decreased with ALP overexpression. The data represent the means ± SD from 
three independent experiments. *P <0.01 vs. Ctrl group; 
#
P < 0.01 vs. Ctrl+IL-
1β group.  
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Figure 6. ALP is a negative regulator of NF-κB in colon cancer HT29 
cells 
(A) Western assays, showing either overexpression or shRNA-mediated 
knock down of ALP in colon cancer HT29 cells. (B) Luciferase assay of 
NF-κB in HT29 cells, showing that overexpression of ALP decreased 
NF-κB activation, whereas reduced ALP expression further enhanced 
NF-κB activation. The data represent the means ± SD for three 
experiments. *P < 0.05 vs. Ctrl group. 
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As shown in Figure 7, in HT29 cells, which have constitutively active NF-κB, 
knocking down ALP markedly increased cell growth, whereas increased 
expression of ALP significantly decreased cell growth. These results indicate that 
ALP is a potent suppressor of cell proliferation in these cells. 
Furthermore, in a colony independent assay (soft agar assay), knocking down 
ALP significantly increased the sizes of colonies, while increased expression of 
ALP had opposite effect (Figure 8A and B), strongly suggesting that ALP is a 
potent tumor suppressor of colony formation in human colon cancer HT29 cells. 
Another important aspect for tumor progression is metastasis. In the in vitro 
experimental system, we could perform cell migration assay to examine the 
ability that a cell can migrate. As shown in Figure 9, overexpression of ALP in 
the HT29 cells led to decrease in migration ability as measured by Boyden 
chamber assays. However, the observed decrease in migration was significantly 
reverted when ALP was knocked down. These data suggest that ALP plays an 
important role in mediating migration functions in human colon cancer HT29 
cells. 
3.4 Conditioned media from HT29 cells with ALP overexpression led to 
decreased NF-κB inducing ability as compared to HT29 cell. 
Constitutive NF-κB activation in cancer is often caused by the autocrine action of 
secreted cytokines (Wolf JS et al. 2001; Arlt A et al. 2002; Coward WR et al. 
2002). To test if ALP had an effect on the secretion of activators in culture 
medium, we assayed conditioned media from HT29 cells, and HT29 cells with 
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Figure 7. Effect of ALP on cell proliferation in colon cancer 
HT29 cells 
High levels of ALP decreased cell growth, whereas decreasing 
ALP expression with shRNA increased cell growth in HT29 cells. 
The data represent the means ± SD for three experiments. *P < 
0.05 vs. Ctrl group. 
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Figure 8. Effect of ALP on anchorage independent growth in colon cancer 
HT29 cells 
(A) Images of colonies in a soft agar assay, showing that high levels of ALP 
decreased sizes of colonies formed, whereas decreased expression of ALP 
increased sizes of colonies in HT29 cells. (B) Statistical analysis of the sizes of 
the colonies observed. Results of triplicate assays are shown as means ± SD. *P 
< 0.05 vs. Ctrl group. 
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Figure 9. Effect of ALP on cell migration in colon cancer HT29 cells 
(A) Images of migrated cells in a Boyden chamber assay, showing that high 
levels of ALP decreased the number of migrated cells, whereas decreased 
expression of ALP increased the number of migrated cells in HT29 cells. (B) 
Statistical analysis of the sizes of the colonies observed. Results of triplicate 
assays are shown as means ± SD. *P < 0.05 vs. Ctrl group. 
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both overexpression and shRNA knock down of ALP. Normal cell culture media 
was used as basal control. As shown in Figure 10, a well-established 293-κB 
reporter cell line (Lu T et al. 2004) was used; different media secreted from the 
above HT29 cells were used to treat this 293-κB reporter cell line. Data 
suggested that media from the HT29 cells with ALP overexpression had 
decreased NF-κB inducting ability as compared to that of HT29 cells. On the 
other hand, media from shRNA for ALP showed greatly increased NF-κB 
inducing ability, strongly suggesting that ALP negatively regulates NF-κB 
signaling and knocking it down leads to the activation of NF-κB, partially through 
the action of secreted factors. 
3.5 ALP expression is reduced in different human colon cancer cell lines 
and is gradually lost with tumor progression in CRC 
The expression of ALP was examined in human colon tissues using 
immunochemical staining. The combination of IHC and tissue microarray (TMA) 
technology allows for the simultaneous in-situ protein expression analysis in 
hundreds of tissue samples. The expression of the ALP protein was observed 
and scored by IHC on the TMA, which included 40 colon adenocarcinoma and 8 
normal colon tissues. IHC result showed that the ALP protein was heavily stained 
in normal colon tissue, while as the cancer progressed, a lesser staining could 
also be observed (Figure 11A). Digital image analysis (Aperio ScanScope) 
revealed the percentage of Aperio positive staining for ALP protein, brown tissue 
nuclei corresponding to positive ALP staining. We observed that the advanced 
stages of CRC showed ALP negative tumor nuclei. Figure 11B, represents the  
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Figure 10. Assays of conditioned media 
Conditioned media from colon cancer HT29 cells overexpressing ALP protein 
had lower NF-κB-inducing activity than media from HT29 cells, whereas 
conditioned media from HT29 cells with reduced ALP protein had much higher 
NF-κB-inducing activity than media from HT29 cells. Ctrl (control) represents 
the regular cell culture media. Stable 293-NF-κB reporter cells were used. The 
data were normalized to the total number of cells that generated the 
conditioned media and to the total amounts of protein. The data represent the 
means ± SD from three independent experiments. *P < 0.05 vs. HT29 group. 
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scoring results obtained from the pathologist (Dr. George Sandusky). Taken 
together, these data demonstrate the loss of expression of ALP with tumor 
progression in human colon tissue. 
3.6 Initial exploration of the causes of loss of ALP in CRC 
Cancer cells are characterized by increased transcription of tumor promoter 
genes and decreased transcription of tumor suppressor genes. Also, DNA 
amplifications activate oncogenes and are hallmarks of nearly all advanced 
tumors (Myllykangas S et al. 2006). Thus, in order to examine if there was any 
variation of the mRNA levels or DNA copy number of ALP, we used different 
colon cancer cells like HT29 and DLD1 to carry out both reverse transcription 
polymerase chain reaction (RT-PCR) and genomic PCR, respectively. RT-PCR 
analysis revealed that the mRNA levels of ALP were greatly reduced in different 
colon cancer cell lines as compared to that in 293 normal control cells (Figure 
12A). Additionally, PCR analysis of genomic DNA extracted from these cells 
indicated that the ALP copy number was decreased in colon cancer cell as 
compared to the 293 cells (Figure 12B). GAPDH was used as an endogenous 
control as it was stable among different cell lines of interest. These data not only 
demonstrate that ALP expression is reduced in different groups of colon cancer 
cell lines but also suggest that ALP may serve as a potential marker for the 
diagnosis of CRC. 
3.7 ALP does not affect upstream events of NF-κB signaling  
In order to shed lights onto the molecular mechanism by which ALP inhibits NF-
κB activation, we first examined the phosphorylation and degradation of IκBα. To  
38 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11.Loss of ALP with tumor advancement in human colon 
tissues 
(A) Images of ALP staining pattern in major subtypes of  CRC showing 
the gradual loss of ALP protein upon tumor progression (positive 
staining = brown nuclei) (20X).(B) Quantification of immunostaining 
performed using the automated Aperio ScanScope CS system indicated 
reduced expression of ALP in patient tissues was correlated with 
advanced clinical stage. 
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Figure 12. Reduced levels of ALP mRNA and copy 
number in different colon cancer cell lines 
(A) An RT-PCR experiment followed by agarose gel 
electrophoresis and EtBr staining indicated that the 
mRNA levels of ALP are decreased in HT29 and DLD1 
colon cancer cell lines. (B) Genomic-PCR experiment 
indicated that the ALP copy number is dramatically 
decreased in HT29 and DLD1.  
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test whether ALP functions upstream or downstream of the IKK complex, we 
performed a western analysis, comparing human colon cancer HT29 cells with 
the same cells stably overexpressing or knocked down ALP (Figure 13). Upon 
treatment with IL-1β, the expression of ALP did not affect either the IκBα 
degradation or its resynthesis significantly, indicating that ALP functions 
downstream of the IKK-IκBα axis. 
3.8 ALP binds to the p65 subunit of NF-κB 
To gain further insight into the molecular mechanisms underlying ALP mediated 
NF-κB inhibition, the next logical step was to see if ALP mediates this inhibition 
by directly binding to p65. In order to test this, we treated 293 cells and the same 
cells overexpressing ALP with IL-1β for 1 h. Since ALP is Flag-tagged, we used 
anti-Flag to pull down endogenous ALP, and further carried out western analysis 
to probe for p65. The result clearly shows that ALP binds to p65 in a signal-
dependent manner (Figure 14), suggesting that ALP could perform its NF-κB 
negative regulator function through direct binding to NF-κB. 
3.9 ALP co-localizes with p65 predominantly in the cytoplasm and 
translocates to the nucleus upon NF-κB activation 
To date, the distribution of ALP is completely unknown. We attempted to 
examine the distribution of ALP by immunofluorescence (IF) assay in 293 cells 
(Figure 15), and in human colon cancer HT29 cells (Figure 16). Cells were 
viewed with blue excitation/emission settings to detect 4',6-diamidino-2-
phenylindole (DAPI) staining of the nuclei, with red excitation/emission settings to 
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detect ALP, and with green excitation/emission settings to detect p65. We found 
that ALP protein was predominantly localized in the cytoplasm in 293 cells 
(Figure 15). Some fluorescence is observed in the nucleus. However, a 
proportion of this fluorescence can be attributed to the fluorescence seen using 
the secondary antibody alone, which stains the entire cell faintly. The distribution 
of p65 we observed is consistent with previous studies that showed that p65 is a 
cytoplasmic protein when it is inactive (Espinosa L et al. 2002).  
Double-staining experiments allowed for the simultaneous detection of ALP 
(revealed by red fluorescence) and p65 (revealed by green fluorescence) 
indicated that the two proteins co-localize in the cytoplasmic compartment in the 
colon cancer HT29 cells. We also examined the distribution of ALP/p65 before 
and after IL-1β treatment. IL-1β is a pro-inflammatory cytokine that induces NF-
κB activity. In normal untreated HT29 cells, ALP/p65 spares the nucleus and was 
predominantly cytoplasmic; however, after 30 min of IL-1β treatment and NF-κB 
activation, a large portion of ALP/p65 was found within the nucleus (Figure 16). 
These data indicate that ALP regulates gene expression by a general 
mechanism that may involve its nuclear translocation upon NF-κB activation. 
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Figure 13. Expression of ALP does not affect degradation of IκBα 
significantly 
Western analysis, showed similar pattern in the levels of total IκBα in colon 
cancer HT29 cells and the same cells in which ALP have been over-expressed 
and knocked down, all three cell lines were treated with 10 ng/mL IL-1β.  
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Figure 14. ALP binds to the p65 subunit of NF-κB 
ALP is Flag-tagged; endogenous ALP co-immunoprecipitated 
with p65. 293 cells were treated with 10 ng/mL of IL-1β for 1 h 
or were untreated. ALP bound to p65 even when NF-κB is 
inactivated. 
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Figure 15. ALP is predominantly a cytoplasmic protein 
Endogenous subcellular localization determined by Immunofluorescence 
staining in 293 cells using antibody for ALP (red) and antibody for p65 (green) 
showed that ALP and p65 are predominantly localized in the cytoplasm. 
Images are representative of three independent experiments, counterstained 
with DAPI and taken at 60X magnification. 
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Figure 16. ALP is translocated to the nucleus upon NF-κB activation 
The images (Upper panel) represent the fluorescence distribution of ALP (red) 
and p65 (green) in untreated colon cancer HT29 cells. Immunofluorescence 
staining (Lower panel) of ALP and p65 in HT29 cells after treatment with 10 
ng/mL of IL-1β for 30 min. Images are representative of three independent 
experiments, counterstained with DAPI and taken at 60X magnification. 
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CHAPTER IV DISCUSSION 
 
NF-κB is constitutively active and plays a key role in variety of human diseases 
(Baldwin AS, 2001). NF-κB has recently become a potential target for 
pharmacological intervention. Although more than 700 inhibitors of the NF-κB 
activation pathway have been identified, no NF-κB blocker has been approved 
for human use (Gupta SC et al. 2010). Most of the NF-κB inhibitors act as 
general inhibitors of NF-κB activation, while few others target specific steps in the 
NF-κB pathway. General inhibitors of NF-κB activation lack specificity and thus 
interfere with NF-κB’s physiological roles in immune and inflammatory 
responses, developmental processes, cellular growth, and apoptosis. Thus in 
order to avoid the risk of undesirable side effects, developing NF-κB inhibitors 
aimed to target specific pathways or cells is important. Identification of regulators 
of specific NF-κB activation needs deeper insight into understanding the 
regulation of this pathway, as it would lead to the manipulation of this pathway in 
the clinic and would offer promising strategies for the treatment of diseases. 
Though many small molecule activators associated with specific NF-κB activation 
pathways have been reported, but relatively very few negative regulators have 
been reported to date.  
In this study we report that ALP, a protein with few known biological functions, is 
a negative regulator of NF-κB signaling. We found that ~46% of NF-κB inducible 
genes were significantly down-regulated by increased expression of ALP. These 
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genes encode cytokines, chemokines, kinases, growth factors, and cell-adhesion 
molecules, including SOCS6 (Lai RH et al. 2010), BMP1 (Hwang EY et al. 2014), 
and S100A3 (Schäfer BW et al. 1996), whose roles are widely accepted to be 
essential in tumor progression and invasion. Several members of the Armadillo 
repeat containing superfamily family have been shown to key players in 
regulating cellular signaling, most notable among which is APC, which acts as 
tumor suppressor in CRC (Mundade R et al. 2014). Our data suggested that like 
APC, ALP also has a suppressive role in CRC. Functional data supporting a role 
for ALP in colon cancer were obtained by over-expression of ALP in human colon 
cancer cell line, which led to marked growth suppression, colony formation and 
migration ability of the cancer cells. These data demonstrates the profound effect 
of ALP on biological activity in CRC and may suggest a tumor suppressive role of 
ALP in CRC. The detailed mechanism by which ALP inhibits CRC cell 
proliferation and invasion should be investigated in future work. Although the 
results of the migration analyses may in part be explained by a reduction in cell 
number rather than a change of cell migration ability, the analysis of mRNA 
levels of some cell motility-associated genes such as mitogen-activated protein 
kinase (MAPK), phospholipase C, gamma 2 (PLCG2) in different CRC cells can 
be done in future to confirm this finding.  
Immunohistochemical studies with human colon tissues revealed that ALP 
expression is reduced in a large percentage of CRC tumors compared with non-
tumor tissues and is gradually lost in high-grade tumors. This finding gives rise to 
the possibility that ALP functions as a tumor suppressor, in the context of 
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pathological conditions such as cancer development in actual human samples. 
Our study thus indicate that, inactivation of ALP through genetic and epigenetic 
alterations are common in CRCs, and may contribute to the pathogenic 
development of this malignancy.  
There are multiple mechanisms that lead to copy number variation. The major 
cause of copy number variation is mis-segregation of chromosomes at mitosis or 
meiosis, cohesion and checkpoint defects, non-disjunction or recombination or 
repair events generating dicentric and acentric chromosomes (Lee H et al. 2014). 
In context of cancer cells, increasing number of experiments have revealed that 
copy number variations confer several advantages that may affect the behaviors 
of malignant cells, including cell growth, apoptosis, anticancer drug sensitivity 
and the invasive and metastatic potentials (Wen SL et al. 2013). This link 
between copy number and cancer cell fitness is supported by high-throughput 
profiling of 8,000 cancer genomes, where pan-lineage alterations have been 
linked to kinases and cell cycle regulators (Kim TM et al. 2013). In the present 
study, using genomic PCR analysis, we detected an alteration in the copy 
number of ALP in several human colon cancer cell lines as compared with 
normal cells. Analysis using RT-PCR revealed that, a pervasive loss of ALP gene 
copy number in human CRC cell lines is also associated with an impairment of 
ALP mRNA level in malignant cells.  The positive correlation between gene loss 
and gene expression level indicate that ALP gene might have a transcriptional 
dampening effect. Importantly, these results are the first to identify that ALP is 
the target of frequent copy number loss in human CRC, and this genomic loss is 
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accompanied by a down-regulation of ALP mRNA expression, supporting a 
tumor suppressive role for this gene. Further studies like in vivo approach in the 
mouse to determine whether or not ALP is a haploinsufficient tumor suppressor, 
genome sequencing of CRC cells, RNA-Seq profiles to explore the biological 
consequences of copy number changes in CRC patients and downstream 
products, would be beneficial to understanding the function of ALP genomic DNA 
in malignancy.  
Previous studies have shown that p65 is a cytoplasmic protein and nuclear 
translocation of p65 subunit of NF-κB is required for the expression of a subset of 
NF-κB target genes (Zhang T et al. 2013). In our attempts to see the sub-cellular 
localization of ALP, we found that ALP is predominantly a cytoplasmic protein. In 
the future, we will further confirm the sub-cellular localization identified in this 
study by separating the nuclear and cytoplasmic extracts and doing a Western 
analysis with antibodies to the protein. Further, from our co-immunoprecipitation 
and co-localization experiments, we showed that ALP directly interacts with the 
p65 subunit of NF-κB. Knowing the sub-cellular localization of ALP and that it 
interacts with p65 is a major step in determining the role of ALP in regulating the 
NF-κB signaling. To further examine the effect of ALP on activation of NF-κB, we 
treated the 293 and HT29 cells with cytokine IL-1β to induce NF-κB activity. 
While the non-stimulated cells retained a large portion of ALP/p65 complex, the 
translocation of ALP/p65 complex from cytoplasm to nucleus in cytokine-
stimulated cells was striking. We also showed that ALP works downstream of IKK 
in the NF-κB pathway. Based on these observations we can postulate that, ALP 
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may function as a transcriptional repressor of NF-κB by binding to p65 and 
inhibiting its function. Nevertheless, how this interaction between nuclear NF-κB 
protein p65 and ALP is controlled and regulated is a question that remains 
unresolved. Detecting and characterizing proteins and protein complexes 
associated with ALP using mass spectrometry, meta-analysis of microarray data 
using a pathway-based approach, and possibly looking at different sites of action 
of ALP in the NF-κB pathway will be needed to extend this model further in the 
future. 
Multiple mechanisms are implicated in the negative regulation of NF-κB activity. 
A study published in Science by Jiang Y et al. 1999, demonstrated that SODD 
(silencer of death domains) negatively regulates NF-κB signaling by suppressing 
the ability of tumor necrosis factor (TNF) to activate NF-κB dependent reporter 
gene expression. Overexpression of SODD causes it to associate with the 
intracellular domain of TNFR1, forming the TNFR1-SODD complex thereby 
blocking the association of TNF with its receptor. A study by Heyninck K et al. 
2005, showed that a zinc finger protein A20, negatively regulates NF-κB 
signaling by two opposing activities: sequential de-ubiquitination and 
ubiquitination of the TNF receptor-interacting protein (RIP), thereby targeting RIP 
to proteasomal degradation. Furthermore, it was reported that binding of PIAS1 
(protein inhibitor of activated signal transducers and activators of transcription, 
STAT-1) to p65 inhibits cytokine-induced NF-κB dependent gene activation by 
blocking the DNA binding activity of p65 both in vitro and in vivo (Liu B et al. 
2005). Additionally, it has been identified that B-cell leukemia (Bcl)-3 negatively 
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regulates NF-κB activation in a TLR signaling dependent manner by blocking 
ubiquitination of p50 subunit of NF-κB. Bcl-3 stabilizes p50 complex that inhibits 
gene transcription (Carmody RJ et al. 2007). These are a few of the examples 
demonstrating the multiple mechanisms of NF-κB regulation, and also reiterating 
the complexity of the same. 
Epigenetic properties of the cancer genome correlate with the development and 
function of the cancer cell. Negative regulation of NF-κB signaling at post-
translational level was demonstrated in 2009; Phosphorylation of Serine (Ser) 
536 is essential for the transactivation function of p65 and recruitment of the 
transcriptional co-activator p300. As a negative regulator of NF-κB, WIP1 was 
reported to be a direct phosphatase of Ser 536 of the p65 subunit of NF-κB 
(Chew J et al. 2009). Loss of function or transcriptional silencing via 
hypermethylation has been widely identified for tumor suppressor genes (Ting 
AH et al. 2006). Dr. Lu et al. 2009, identified F-box and leucine-rich repeat 
protein 11 (FBXL11) as another negative regulator of NF-κB (Lu T et al. 2009). 
This important study unfolded yet another mechanism of negative regulation of 
NF-κB signaling. FBXL11 consists of the JmjC domain, which encodes the 
histone H3K36 demethylase activity; this activity is essential for the negative 
regulative effect of FBXL11 on NF-κB through the methylation of the p65 subunit 
of NF-κB. It is also possible that the expression of ALP is gradually down-
regulated in CRC via epigenetic mechanisms, such as DNA hypermethylation. In 
the future, we can perform the methylation-specific PCR (MSP) assay to further 
investigate this possibility. These analyses will not only directly verify the 
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implicated cancer functioning role of ALP, but also will be of particular use in 
tumor biospecific based diagnostics and pathway directed therapeutics. 
In the present study, we provide unique insight regarding how high levels of ALP 
may inhibit tumorigenesis, at least in part by inhibiting NF-κB activation. These 
results open a brand new avenue for future study. An important question for 
future research is to determine the mechanism of regulation of NF-κB signaling 
by ALP. By motif search, we have identified six ARM-repeats in ALP. It is well 
known that ARM-repeats are crucial for interactions with many proteins, whether 
ALP function is regulated by these repeats, and improving their stability may lead 
to a more profound effect on ALPs function remains to be studied. Another area 
that remains to be explored is to understand the causes of reduced ALP 
expression during tumor development, as this will be of fundamental importance 
in understanding the important role of ALP in CRC progression. A detailed 
understanding of how ALP negatively regulates NF-κB signaling will further raise 
the possibility of focusing on ALP as a drug target and biomarker. Furthermore, 
future in vivo experiments will provide a basis for further investigating ALP as a 
tumor suppressor and its inactivation in the pathogenic development of CRC. 
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